Dragos Zanchi, MD
Pulmonary Disease · Brandon, FLNPI 1922068550
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.4%), speaking fees and education — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AstraZeneca at 40.8% of the total. Reporting peaked in 2023 at $12,882 and has fallen 69.3% since, to $3,949 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 948 payments — averaging $47.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Intuitive Surgical$10K
- GSK$4K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Boehringer Ingelheim$952
- Grifols USA, LLC$864
- plus $10K from 54 others
Across 457 payments — averaging $2144.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$435K
- Harmony Biosciences LLC$180K
- Alkermes, Inc.$137K
- Takeda Pharmaceuticals U.S.A., Inc.$121K
- Boehringer Ingelheim$33K
- AstraZeneca$30K
- plus $44K from 4 others
What the payments were for
- Consulting fees$2501%
- Speaking & faculty fees$16,00035%
- Travel & lodging$7012%
- Food & beverage$19,23742%
- Education$9,20320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$13,646
- Da Vinci Surgical System$6,823
- ION$3,000
- BREZTRI AEROSPHERE$2,700
- Inspire$296
- JOENJA$250
- LINX Reflux Management System$148
- XYREM$125
How this compares
$45,391 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,545 | $1,209,464 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 79 | $964,487 |
| OfevNintedanib Esylate | 64 | $854,046 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 570 | $422,150 |
| Spiriva RespimatTiotropium Bromide | 570 | $361,054 |
| GlassiaAlpha-1-Proteinase Inhibitor | 20 | $282,442 |
| SymbicortBudesonide/Formoterol Fumarate | 817 | $228,543 |
| Spiriva HandihalerTiotropium Bromide | 194 | $166,253 |
| Breo ElliptaFluticasone/Vilanterol | 294 | $148,319 |
| WakixPitolisant Hcl | 12 | $95,217 |
| TezspireTezepelumab-Ekko | 20 | $89,426 |
| Dupixent PenDupilumab | 23 | $85,576 |
| XolairOmalizumab | 14 | $78,185 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 134 | $75,354 |
| Incruse ElliptaUmeclidinium Bromide | 168 | $70,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $3,939 | $1,503,1692,141 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $952 | $1,295,661767 claims |
| Grifols USA, LLCProlastin C | $864 | $964,48779 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Tezspire | $18,513 | $740,1191,407 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $1,213 | $282,44220 claims |
| Harmony Biosciences LLCWakix | $612 | $95,21712 claims |
| Genentech, Inc.Xolair | $47 | $78,18514 claims |
| Lilly USA, LLCMounjaro | $41 | $21,06722 claims |
| Hikma Pharmaceuticals USARyaltris | $17 | $3,72715 claims |
| MerckDulera | $56 | $3,53411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Brandon
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.